Eachy Biopharmaceuticals specializes in the research and development of in vitro diagnostic products, particularly focusing on cardiac biomarkers and the detection of vulnerable plaques associated with atherosclerosis. The company has developed a range of diagnostic kits aimed at the early detection and risk assessment of various cardiovascular diseases, including Acute Myocardial Infarction (AMI) and Heart Failure. Their innovative approach includes the use of Fully Automated Chemiluminescence Immunoassay technology, which allows for rapid and accurate testing. Eachy has successfully launched several products, such as MPO, HFABP, and Lp-PLA2, which are currently utilized in over 200 hospitals, showcasing their commitment to advancing healthcare through continuous innovation.

In addition to their existing products, Eachy is actively addressing gaps in the Point-of-Care Testing (POCT) market by developing advanced diagnostic tools for early detection of acute coronary syndrome and diabetic nephropathy. Their patented products include a combination test for early detection of acute coronary syndrome and a home test kit that can predict risks up to six months in advance. Eachy’s diagnostic solutions are designed to provide timely results, with some tests delivering outcomes within just a few hours, significantly enhancing the ability to manage and treat cardiovascular and metabolic conditions effectively.

China

Eachy Biopharmaceuticals, Ltd is a ISO 13485 qualified company focused on developing and producing in vitro diagnostics for the prognosis of cardiovascular diseases, metabolic syndrome and the diagnosis of inflammatory diseases.AccuRapid SARS-CoV-2 IgM/IgG Test Kit (Lateral Flow Immunoassay) - EU CE Mark 32020

Eachy Biopharmaceuticals

Company Details